Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC

Lung Cancer Clinical Trial

Official title:

Autologous Dendritic Cell-cytokine Induced Killer Cell Immunotherapy Combined Anti-PD1 in Advanced NSCLC: A Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03360630
• Other study ID #: PD-1 plus DC-CIK for NSCLC
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 1, 2016
• Est. completion date: June 1, 2023

Study information

• Verified date: February 2024
• Source: Capital Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized controlled study to compared the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells administered with anti-PD-1 antibody in advanced NSCLC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: June 1, 2023
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed advanced or metastatic NSCLC.

• Patients must have received previously standard therapy for that malignancy or declined to chemotherapy/radiotherapy.

• Estimated life expectancy > 3 months.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.

• Age 18 to 80.

• Adequate hematologic function, with WBC = 3000/microliter, hemoglobin = 9 g/dL (it is acceptable to have had prior transfusion), platelets = 75,000/microliter; PT-INR <1.5 (unless patient is receiving warfarin in which case PT-INR must be <3), PTT <1.5X ULN

• Adequate renal and hepatic function, with serum creatinine < 1.5 mg/ dL, bilirubin < 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin = 2.0 mg/dL), ALT and AST = 2.5 x upper limit of normal.

Exclusion Criteria:

• Patients with a history of autoimmune disease, such as but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. Autoimmune related thyroid disease and vitiligo are permitted.

• Patients with serious intercurrent chronic or acute illness, such as cardiac disease (NYHA class III or IV), hepatic disease, or other illness considered by the Principal Investigator as unwarranted high risk for investigational drug treatment.

• Patients with a medical or psychological impediment to probable compliance with the protocol should be excluded.

• Concurrent (or within the last 5 years) second malignancy other than non melanoma skin cancer, cervical carcinoma in situ, controlled superficial bladder cancer, or other carcinoma in situ that has been treated.

• Presence of an active acute or chronic infection including: a urinary tract infection, HIV (as determined by ELISA and confirmed by Western Blot). Patients with HIV are excluded based on immuno-suppression, which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections.

• Patients on chronic steroid therapy (or other immuno-suppressives, such as azathioprine or cyclosporin A) are excluded on the basis of potential immune suppression. Patients must have had 6 weeks of discontinuation of any steroid therapy (except that used as pre-medication for chemotherapy or contrast-enhanced studies or for acute treatment (<5 days) of intercurrent medical condition such as a gout flare) prior to enrollment.

• Pregnant and nursing women should be excluded from the protocol since this research may have unknown and harmful effects on an unborn child or on young children. If the patient is sexually active, the patient must agree to use a medically acceptable form of birth control while receiving treatment and for a period of 4 months following the last vaccination therapy. It is not known whether the treatment used in this study could affect the sperm and could potentially harm a child that may be fathered while on this study.

• Patients with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded.

Related Conditions & MeSH terms

• Lung Cancer
• Neoplasms

Intervention

Biological:
• Anti-PD-1 plus DC-CIK
Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal. DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
• Anti-PD-1 alone
Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.

Locations

Country	Name	City	State
China	Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital	Beijing

Sponsors (3)

Lead Sponsor	Collaborator
Capital Medical University	Duke University, Geneplus-Beijing Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Cell-free tumor DNA	To investigate the relationship of ctDNA with clincial outcomes	24 months
Other	Tumor related antigen peptides	To investigate the relationship of tumor related antigen peptides with clincial outcomes	24 months
Other	T cell metaboic activity	To investigate the relationship of T cell metaboic activity with clincial outcomes	24 months
Other	Microbial bacteria	To investigate the relationship of microbial bacteria with clincial outcomes	24 months
Primary	Progression-free survival of the participants	From starting date of anti-PD-1 antibody treatment until date of until the date of first documented disease progression or date of death from any cause, whichever comes first.	12 months
Secondary	Overall survival of the participants(OS)	From starting date of anti-PD-1 antibody treatment until date of death from any cause	24 months
Secondary	Assessment of Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PROCTCAE)	To assess and compare the PRO-CTCAE by patients receiving immunotherapy	24 months
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0		24 months
Secondary	Molecular Tumor Burden Index	Using mutation detection in ctDNA by liquid biopsy to assess tumor dynamics	24 months